The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: a Phase 3, randomized, double-blind, placebo-controlled study

Highlights • Tofacitinib is an oral Janus kinase inhibitor. • Tofacitinib showed superior efficacy vs placebo in Asian patients with psoriasis. • No unexpected safety findings were observed in Asian patients vs global studies.

Saved in:
Bibliographic Details
Published in:Journal of dermatological science 2017-10, Vol.88 (1), p.36-45
Main Authors: Zhang, JianZhong, Tsai, Tsen-Fang, Lee, Min-Geol, Zheng, Min, Wang, Gang, Jin, HongZhong, Gu, Jun, Li, RuoYu, Liu, QuanZhong, Chen, Jin, Tu, CaiXia, Qi, ChunMei, Zhu, Hua, Ports, William C, Crook, Tim
Format: Article
Language:English
Subjects:
Administration, Oral
Adult
Asia
Asian Continental Ancestry Group
China
Dermatology
Double-Blind Method
Efficacy
Female
Humans
Janus kinase inhibitor
Janus Kinases - antagonists & inhibitors
Male
Middle Aged
Piperidines - therapeutic use
Plaque psoriasis
Protein Kinase Inhibitors - therapeutic use
Psoriasis - drug therapy
Pyrimidines - therapeutic use
Pyrroles - therapeutic use
Republic of Korea
Safety
Severity of Illness Index
Taiwan
Tofacitinib
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Tofacitinib is an oral Janus kinase inhibitor. • Tofacitinib showed superior efficacy vs placebo in Asian patients with psoriasis. • No unexpected safety findings were observed in Asian patients vs global studies.
ISSN:0923-1811
1873-569X
DOI:10.1016/j.jdermsci.2017.05.004